NasdaqGS:HALOBiotechs
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' (HALO) Investment Narrative?
In recent weeks, Halozyme Therapeutics reported record 2025 revenue of about US$1.40 billion, highlighted growing ENHANZE-driven royalties, and outlined progress integrating its Hypercon and Surf Bio acquisitions, while also securing new global collaborations and regulatory approvals for ENHANZE-enabled products.
Against this backdrop, CEO Helen Torley’s appearance at the TD Cowen Health Care Conference offers investors fresh context on how Halozyme aims to build on its high-margin,...